Locally Advanced NSCLC Implementing Innovation

Slides:



Advertisements
Similar presentations
Advances and Emerging Therapy for Lung Cancer
Advertisements

Prospective Phase I/II Trial of Carbon Ion Radiotherapy for Locally Advanced Non-small-cell Lung Cancer (NSCLC) Abstract title: CIRT for Locally Advanced.
이근욱 분당서울대학교병원/서울의대 혈액종양내과 부교수
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
ESMO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR mDR
Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in.
CCO Independent Conference Highlights
Statistical Considerations for Safety Assessment in Cancer Immunotherapy Trials Andrew Lloyd Biometrics Manager PSI Conference May 2017.
Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck
Securing the cure in resectable lung cancer
Bladder Cancer: A New Era in Treatment
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Intervista a Lucio Crinò
Intervista a Angelo Delmonte
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Patient Case 1 Patient Case 1: PET/CT Scan.
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.
Treatment Algorithms in Melanoma: Past, Present, and Future
The Immune System. The Immune System Adaptive Immune Response.
Advanced NSCLC Without Actionable Mutations
State of the Art in HCC: Immune Checkpoint Modulation
New Patient Journeys in Non-small cell lung cancer
Immunotherapy Combinations for Lung Cancers
Progression After Cancer Immunotherapy in Advanced NSCLC
The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer
Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.
The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.
Activity Goals. Activity Goals Discussion Topics.
Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.
The Evolving Role of Immunotherapy in NSCLC
New developments in oncological treatment for Stage 3 NSCLC
Optimizing Management of Advanced Bladder Cancer
Checkpoint Inhibition
EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?
Basics of Immunotherapy Potential Therapeutic Targets.
Managing gBRCA-Positive Metastatic Breast Cancer
Advanced Lung Cancers: What's on the Horizon?
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Immunotherapy.
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Evolving Concepts in the Management of Head and Neck Cancers
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Oncologia Polmonare – AOU S. Luigi Gonzaga, Orbassano (To)
Immune Checkpoint Inhibitors in Lung Cancer
Locally Advanced Lung Cancer
Advances in Gastrointestinal Cancers
Treatment of Locally Advanced Pancreatic Cancer
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.
What’s new in stage III lung cancer?
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
Preparing for Checkpoint Inhibitors in Breast Cancer
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Educational Objectives
Moving Care Forward in Advanced Gastric Cancer
Immune Checkpoint Inhibitors in Lung Cancer
Combining Immunotherapy and Chemotherapy in NSCLC
Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.
Results: Purpose/Objectives: Methods: Conclusions:
Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Updates in Best Practices in Non-Small Cell Lung Cancer
Glucose levels must be monitored in patients receiving steroids for immunotherapy-related toxicity Title: Subtitle Risk Assessment of Hyperglycaemia Induced.
Presentation transcript:

Locally Advanced NSCLC Implementing Innovation

Program Agenda

Current Standards in Locally Advanced (Stage III) NSCLC

International Standards for CRT for Locally Advanced (Stage 3) NSCLC

How Do We Plan Radiation?

ESMO Recommendations for Locoregional NSCLC

ESMO Recommendations continued

Overall Survival and Toxicity Associated With RT

Implementing New Data and Evolving Standards

Rationale Radiation + Immunotherapy

Pembrolizumab + Prior Radiation

PACIFIC Study

PFS in the ITT Population

Best Practices for Scanning After CRT

Rationale for Performing Scan Immediately Following CRT

Safety of Checkpoint Inhibitors

PACIFIC Trial: Adverse Events

Pneumonitis or Radiation Pneumonitis

Monitoring for imAEs

PACIFIC Trial: Discussion Topics

What Next?

Panel Discussion and Audience Question & Answer

PACIFIC PFS in the Intention-to-Treat Patients

How Do We Integrate New Data Into Practice?

Neoadjuvant Nivolumab Yielded Pathologic Responses in Resectable Lung Cancer

Discussion Topics

Concluding Remarks